A Study to Evaluate SAGE-217 in Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode - Part A
Status:
Completed
Trial end date:
2019-03-23
Target enrollment:
Participant gender:
Summary
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and
efficacy of SAGE-217 in the treatment of subjects with bipolar I/II disorder with a current
major depressive episode.